| Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients A Forrest, DE Nix, CH Ballow, TF Goss, MC Birmingham, JJ Schentag Antimicrobial agents and chemotherapy 37 (5), 1073-1081, 1993 | 1421 | 1993 |
| Relationship of MIC and Bactericidal Activity to Efficacy of Vancomycin for Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia G Sakoulas, PA Moise-Broder, J Schentag, A Forrest, RC Moellering Jr, ... Journal of clinical microbiology 42 (6), 2398-2402, 2004 | 1072 | 2004 |
| A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis RL Greenman, RMH Schein, MA Martin, RP Wenzel, NR Maclntyre, ... Jama 266 (8), 1097-1102, 1991 | 970 | 1991 |
| Pharmacodynamics of Vancomycin and Other Antimicrobials in Patients with Staphylococcus aureus Lower Respiratory Tract Infections PA Moise-Broder, A Forrest, MC Birmingham, JJ Schentag Clinical pharmacokinetics 43, 925-942, 2004 | 914 | 2004 |
| Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions JA Roberts, MH Abdul-Aziz, J Lipman, JW Mouton, AA Vinks, TW Felton, ... The Lancet infectious diseases 14 (6), 498-509, 2014 | 913 | 2014 |
| Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals: a challenge to hospital leadership DA Goldmann, RA Weinstein, RP Wenzel, OC Tablan, RJ Duma, ... Jama 275 (3), 234-240, 1996 | 895 | 1996 |
| Telemetry capsule and process JJ Schentag, DT D'andrea US Patent 5,279,607, 1994 | 785 | 1994 |
| Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy JK Thomas, A Forrest, SM Bhavnani, JM Hyatt, A Cheng, CH Ballow, ... Antimicrobial agents and chemotherapy 42 (3), 521-527, 1998 | 684 | 1998 |
| Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin … MP Fink, DR Snydman, MS Niederman, KV Leeper Jr, RH Johnson, ... Antimicrobial agents and chemotherapy 38 (3), 547-557, 1994 | 572 | 1994 |
| Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program MC Birmingham, CR Rayner, AK Meagher, SM Flavin, DH Batts, ... Clinical Infectious Diseases 36 (2), 159-168, 2003 | 547 | 2003 |
| Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T> MIC) as predictors of outcome for cefepime and ceftazidime in … PS McKinnon, JA Paladino, JJ Schentag International journal of antimicrobial agents 31 (4), 345-351, 2008 | 539 | 2008 |
| The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome: focus on antibacterial agents JM Hyatt, PS McKinnon, GS Zimmer, JJ Schentag Clinical pharmacokinetics 28, 143-160, 1995 | 500 | 1995 |
| Applied pharmacokinetics: principles of therapeutic drug monitoring WE Evans, JJ Schentag, WJ Jusko (No Title), 1992 | 464 | 1992 |
| Sampling capsule and process DT D'andrea, JJ Schentag US Patent 5,395,366, 1995 | 452 | 1995 |
| Accessory Gene Regulator Group II Polymorphism in Methicillin-Resistant Staphylococcus aureus Is Predictive of Failure of Vancomycin Therapy PA Moise-Broder, G Sakoulas, GM Eliopoulos, JJ Schentag, A Forrest, ... Clinical infectious diseases 38 (12), 1700-1705, 2004 | 441 | 2004 |
| The burden of Staphylococcus aureus infections on hospitals in the United States: an analysis of the 2000 and 2001 Nationwide Inpatient Sample Database GA Noskin, RJ Rubin, JJ Schentag, J Kluytmans, EC Hedblom, ... Archives of internal medicine 165 (15), 1756-1761, 2005 | 434 | 2005 |
| Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development CC Peck, WH Barr, LZ Benet, J Collins, RE Desjardins, DE Furst, ... Journal of pharmaceutical sciences 81 (6), 605-610, 1992 | 371 | 1992 |
| Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme CR Rayner, A Forrest, AK Meagher, MC Birmingham, JJ Schentag Clinical pharmacokinetics 42, 1411-1423, 2003 | 341 | 2003 |
| Pharmacokinetic and clinical studies in patients with cimetidine-associated mental confusion JJ Schentag, G Calleri, JQ Rose, FB Cerra, E Deglopper, H Bernhard The Lancet 313 (8109), 177-181, 1979 | 307 | 1979 |
| Factors affecting theophylline clearances: age, tobacco, marijuana, cirrhosis, congestive heart failure, obesity, oral contraceptives, benzodiazepines, barbiturates, and ethanol WJ Jusko, MJ Gardner, A Mangione, JJ Schentag, JR Koup, JW Vance Journal of pharmaceutical sciences 68 (11), 1358-1366, 1979 | 305 | 1979 |
Charles PeloquinProfessor of Pharmacy, University of Florida在 cop.ufl.edu 的电子邮件经过验证
